EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Biology and Therapeutic Potential of the Interleukin-4/Interleukin-13 Signaling Pathway in Asthma

David B Corry, Farrah Kheradmand

American Journal of Respiratory Medicine · 2002

DOI: 10.1007/bf03256608 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Respiratory Medicine, 2002. Verfasst von David B Corry und 1 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Medicine and the Biology of Inflammation Center, Baylor College of Medicine, Houston, Texas 77030, USA. dcorry@bcm.tmc.edu. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 103 Literaturangaben. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The future management of patients with allergic asthma is poised to change in the coming one to two decades. This prediction is based on fundamental new insights into the pathogenesis of disease, gained through the study of both humans and experimental models of asthma. These studies have revealed that allergic asthma is an immune-mediated disease which, despite the redundancy characteristic of all immune responses, may be induced through a single dominant signaling cascade called the interleukin (IL)-4/IL-13 signaling pathway. In addition to the cytokine IL-4, this pathway includes IL-13, the cytokine receptor subunit IL-4 receptor alpha (IL-4Ralpha), Janus-associated tyrosine kinases and the transcription factor, signal transducer and activator of transcription 6. The IL-4 signaling pathway controls the most important cellular developmental (afferent) events that underlie asthma. These include T helper (Th) type 2 cell activation, B cell activation and immunoglobulin (Ig) E secretion, mast cell development, and effector (efferent) events related exclusively to immune effects on the lung such as goblet cell metaplasia and airway hyperresponsiveness. Any of the IL-4 signaling molecules are potentially amenable to pharmacological intervention, but a detailed understanding of the entire pathway is required to appreciate their actual potential for drug development. For example, neutralization strategies that target only IL-4 are unlikely to succeed because they leave IL-13 free to continue the signaling cascade. In contrast, neutralization of IL-4Ralpha may represent a more feasible strategy, as it should prevent signaling by both IL-4 and IL-13. The therapeutic potential of targeting intracytoplasmic tyrosine kinases has already been achieved with the use of small molecules, suggesting that this approach may be realistically adopted for the treatment of asthma. However, well designed asthma clinical trials are warranted to determine with certainty, the efficacy of therapies based on IL-4/IL-13 blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsAnti-Asthmatic AgentsAsthmaClinical Trials as TopicDisease Models, AnimalDrugs, InvestigationalHumansInterleukin-13Interleukin-4Signal Transduction

Substanzen

Anti-Asthmatic AgentsDrugs, InvestigationalInterleukin-13Interleukin-4

Autor:innen und Institutionen

  • Departments of Medicine and the Biology of Inflammation Center, Baylor College of Medicine, Houston, Texas 77030, USA. dcorry@bcm.tmc.edu

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Corry, D. B., & Kheradmand, F. (2002). Biology and Therapeutic Potential of the Interleukin-4/Interleukin-13 Signaling Pathway in Asthma. American Journal of Respiratory Medicine. https://doi.org/10.1007/bf03256608

Vancouver

Corry DB, Kheradmand F. Biology and Therapeutic Potential of the Interleukin-4/Interleukin-13 Signaling Pathway in Asthma. American Journal of Respiratory Medicine. 2002. doi:10.1007/bf03256608

BibTeX
@article{Corry2002,
  author = {Corry, David B and Kheradmand, Farrah},
  title = {Biology and Therapeutic Potential of the Interleukin-4/Interleukin-13 Signaling Pathway in Asthma},
  journal = {American Journal of Respiratory Medicine},
  year = {2002},
  doi = {10.1007/bf03256608}
}
Kostenlos starten →